Biopharmaceutical developer Cytogen said that it has been notified by the Nasdaq Stock Market that it has regained compliance with the Nasdaq’s listing standard for minimum bid price. To return to compliance, the Princeton, NJ-based vendor performed a 1-for-10 reverse stock split in late October.
By AuntMinnie.com staff writers
November 12, 2002
Copyright © 2002 AuntMinnie.com